

Attach #8
RECEIVED
 FEB 22 2002
 TECH CENTER 1600/2900

**INFORMATION DISCLOSURE
 CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1579-579

09/875,264

APPLICANT


NAIR et al

FILING DATE

GROUP

June 7, 2001

(Use several sheets, if necessary)


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mu	6,306,388	10/2001	Nair et al			
mu	5,827,642	10/1998	Riddell et al			
mu	4,918,164	4/1990	Hellstrom et al			
mu	5,662,907	9/1997	Kubo et al			
mu	6,130,087	10/2000	Srivastava et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

mu	Rouse et al, "Induction In Vitro of Primary Cytotoxic T-Lymphocyte Responses with DNA Encoding Herpes Simplex Virus Proteins", Journal of Virology 68(9):5685-5689 (1994)
	Riddell et al, "Class 1 MHC-Restricted Cytotoxic T Lymphocyte Recognition of Cells Infected With Human Cytomegalovirus Does Not Require Endogenous Viral Gene Expression", The Journal of Immunology 146(8):2795-2804 (1991)
	Boczkowski et al, "Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells In Vitro and In Vivo", J. Exp. Med. 284:465-472 (1996)
	Rabinovich et al, "Vaccine Technologies: View to the Future", Science 265:1401-1404 (1994)
	Morel et al, "Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?", Cancer Gene Therapy 5(2):92-100 (1998)
	Gomez-Navarro et al, "Gene Therapy for Cancer", European Journal of Cancer 35(6):867-885 (1999)
	Sprent et al, "Lymphocyte Life-Span and Memory", Science 265:1395-1399 (1994)
	Oldstone et al, "How Viruses Escape from Cytotoxic T Lymphocytes: Molecular Parameters and Players", Virology 234:179-185 (1997) Article No. VY978674
	Pardoll, "Cancer Vaccines", Nature Medicine Vaccine Supplement 4(5):525-531 (1998)
mu	Cohen et al, "Bumps on the Vaccine Road", Science 265:1371 (1994)
	Gura, "Cancer Models", Systems for Identifying New Drugs Are Often Faulty, Science 278:1041-1042 (1997)

*Examiner

Date Considered

2.4.03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

RECEIVED

FEB 22 2002

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

1579-579

09/875,264

APPLICANT

NAIR et al

FILING DATE

GROUP

(Use several sheets if necessary)

FEB 20 2002

June 7, 2001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mw	5,831,068	11/1998	Nair et al	—	—	
mw	5,853,719	12/1998	Nair et al	—	—	

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
mw	WO 94/04171	3/1994	PCT	—	—
mw	WO 94/04557	3/1994	PCT	—	—
mw	WO 97/41210	11/1997	PCT	—	—

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

mw	Crusinberry et al, "Immunotherapy of Renal Cell Cancer", Seminars in Surgical Oncology 7:221-229 (1991)
	Rosenberg et al, "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients With Metastatic Melanoma", The New England Journal of Medicine 319(25):1676-1680 (1998)
	Donis-Keller, H., "Site specific enzymatic cleavage of RNA", Nucleic Acids Research 7(1):179-192 (1979)
	Friedman, H., "Discussion Paper: Protective Immunity in Leukemic Mice Treated with Specific "Immunogenic" RNA", Annals New York Academy of Sciences 277(00):708-715 (1976)
	Greenup et al, "Anti-Tumor Cytotoxicity of Poly(A)-Containing Messenger RNA Isolated From Tumour-Specific Immunogenic RNA", Br. J. Cancer 38:55-63 (1978)
	Aarons et al, "Immune RNA Therapy as an Effective Adjuvant Immunotherapy After Surgery: An Animal Model", Journal of Surgical Oncology 23:21-26 (1983)
	Porgador et al, "Combined Vaccination with Major Histocompatibility Class I and Interleukin 2 Gene-transduced Melanoma Cells Synergizes the Cure of Postsurgical Established Lung Metastases", Cancer Research 55:4941-4949 (1995)
	Röttschke et al, "Exact prediction of a natural T cell epitope", Eur. J. Immunol. 21:2891-2894 (1991)
	van den Bosch et al, "T-Cell-Independent Macrophase Activation in Mice Induced with rRNA from <i>Listeria monocytogenes</i> and Dimethyldioctadecylammonium Bromide", Infection and Immunity 53(3):611-615 (1986)
	Boon et al, "Human Tumor Antigens Recognized by T Lymphocytes", J. Exp. Med. 183:725-729 (1996)
	Rifkind et al, "Delayed Hypertensitivity to Fungal Antigens in Mice. II. Molecular Classes in Immunogenic RNA Extracts that Transfer Delayed Hypersensitivity", The Journal of Infectious Diseases 133(5):523-532 (1976)
	Rifkind et al, "Delayed Hypersensitivity to Fungal Antigens in Mice. III. Characterization of the Active Component in Immunogenic RNA Extracts", The Journal of Infectious Diseases 133(5):533-537 (1976)
	Nair et al, "Cells Treated with TAP-2 Antisense Oligonucleotides Are Potent Antigen-Presenting Cells In Vitro and In Vivo", The Journal of Immunology 156:1772-1780 (1996)
	Inada et al, "Comparison of the Ability of Lactate Dehydrogenase-Elevating Virus and Its Virion RNA To Infect Murine Leukemia Virus-Infected or -Uninfected Cell Lines", Journal of Virology 67(9):5698-5703 (1993)
	Duke et al, "In Vitro Induction of Antibody Formation With Immunogenic RNA", Annals New York Academy of Sciences 207:145-159 (1973)
	Garvey et al, "Characterization of RNA-Antigen Complexes", Annals New York Academy of Sciences 207:258-278 (1973)
	Dodd et al, "Immunogenic RNA in the Immunotherapy of Cancer: The Transfer of Antitumor Cytotoxic Activity and Tuberculin Sensitivity to Human Lymphocytes Using Xenogeneic Ribonucleic Acid", Annals New York Academy of Sciences 207:454-467 (1973)
mw	Walker et al, "Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen presentation pathway", Proc. Natl. Acad. Sci. USA 89:7915-7918 (1992)
*Examiner	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

